AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1803995 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine with high-dose acyclovir
Number of subjects: 41
Study 6519349 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin/Caffeine combination (800 mg aspirin, 65 mg caffeine)
Number of subjects: 500
Study 6519349 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen/Aspirin combination (648 mg acetaminophen, 648 mg aspirin)
Number of subjects: 500
Study 6519349 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg)
Number of subjects: 500
Study 6519349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 31292983 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate provisionalization (non-occluding temporary crown)
Number of subjects: 40
Study 31292983 — intervention group
Group type: COMPARATOR
Intervention: Healing abutment (no provisionalization)
Number of subjects: 40
Study 28141781 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone (10 mg)
Number of subjects: 45
Study 28141781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 26498405 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative methods in a randomized controlled trial (RCT) of a complex community intervention
Number of subjects: 0
Study 26498405 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed methods approach (qualitative and quantitative)
Number of subjects: 0
Study 26498405 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative research
Number of subjects: 0
Study 23521532 — intervention group
Group type: COMPARATOR
Intervention: Standard evening meal
Number of subjects: 28
Study 23521532 — intervention group
Group type: EXPERIMENTAL
Intervention: Test evening meal enriched in protein (300 g of 0%‐fat fromage frais)
Number of subjects: 28
Study 21159889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancolonic chromoendoscopy (PCC) with 0.4% indigo carmine spraying during continuous extubation
Number of subjects: 1008
Study 21159889 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy (control group)
Number of subjects: 1008
Study 21159889 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC
Number of subjects: 1008
Study 21159889 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1008
Study 19460503 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and Mycophenolate Mofetil (TAC)
Number of subjects: 60
Study 19460503 — intervention group
Group type: COMPARATOR
Intervention: Everolimus and low-dose Cyclosporine (EVL)
Number of subjects: 60
Study 17509729 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program including performance feedback, clinician education, and patient educational materials.
Number of subjects: 16
Study 17509729 — intervention group
Group type: COMPARATOR
Intervention: Control sites (no educational intervention).
Number of subjects: 16
Study 15382101 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-layer bandages
Number of subjects: 0
Study 15382101 — intervention group
Group type: COMPARATOR
Intervention: Short-stretch bandages
Number of subjects: 0
Study 12488062 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 8
Study 12488062 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 8
Study 12488062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9684948 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum extract WS 5572 (5% hyperforin)
Number of subjects: 147
Study 9684948 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum extract WS 5573 (0.5% hyperforin)
Number of subjects: 147
Study 9684948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 7988130 — intervention group
Group type: EXPERIMENTAL
Intervention: Bird VIP ventilator
Number of subjects: 9
Study 7988130 — intervention group
Group type: COMPARATOR
Intervention: Siemens Servo 900C ventilator
Number of subjects: 9
Study 7988130 — intervention group
Group type: COMPARATOR
Intervention: Newport Wave E200 ventilator
Number of subjects: 9
Study 2679843 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 200
Study 2679843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 770329 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuated rubella virus vaccine (administered by nose drops or subcutaneous route)
Number of subjects: 0
Study 770329 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 770329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nose drops and subcutaneous route groups
Number of subjects: 0
Study 31891374 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cups of instant regular coffee (n = 62)
Number of subjects: 126
Study 31891374 — intervention group
Group type: COMPARATOR
Intervention: 4 cups of a coffee-like placebo beverage (n = 64)
Number of subjects: 126
Study 31640806 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health Continuum-Short Form (MHC-SF)
Number of subjects: 1175
Study 28768651 — intervention group
Group type: EXPERIMENTAL
Intervention: RCE (60 mg isoflavone aglycones/d and probiotics)
Number of subjects: 78
Study 28768651 — intervention group
Group type: COMPARATOR
Intervention: Control (masked placebo)
Number of subjects: 78
Study 26939312 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Appliance (FA) with brackets and wires
Number of subjects: 64
Study 26939312 — intervention group
Group type: COMPARATOR
Intervention: Removable Appliance (RA) comprising acrylic plates with protruding springs
Number of subjects: 64
Study 26939312 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Appliance (FA)
Number of subjects: 64
Study 26939312 — intervention group
Group type: COMPARATOR
Intervention: Removable Appliance (RA)
Number of subjects: 64
Study 26939312 — intervention group
Group type: COMPARATOR
Intervention: Both Fixed and Removable Appliances
Number of subjects: 64
Study 23983256 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil/leucovorin (5FU/LV)
Number of subjects: 607
Study 23983256 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil/leucovorin (5FU/LV) with irinotecan (IFL)
Number of subjects: 607
Study 21914263 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy without internal limiting membrane peeling (non-gas tamponade group)
Number of subjects: 49
Study 21914263 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy without internal limiting membrane peeling but combined with gas tamponade (gas tamponade group)
Number of subjects: 49
Study 21914263 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgical treatment)
Number of subjects: 49
Study 19721215 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard protocol (Std): 100‐Hz, 450‐micros pulses, amplitude set to evoke 75% of maximal voluntary isometric torque (MVIT)
Number of subjects: 7
Study 19721215 — intervention group
Group type: EXPERIMENTAL
Intervention: Short pulse duration protocol (SP): 100‐Hz, 150‐micros pulses, amplitude set to evoke 75% of MVIT
Number of subjects: 7
Study 19721215 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency protocol (LF): 25‐Hz, 450‐micros pulses, amplitude set to evoke 75% of MVIT
Number of subjects: 7
Study 19721215 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-amplitude protocol (LA): 100‐Hz, 450‐micros pulses, amplitude set to evoke 45% of MVIT
Number of subjects: 7
Study 19721215 — intervention group
Group type: EXPERIMENTAL
Intervention: Torque per active area (calculated from a companion study)
Number of subjects: 7
Study 17597267 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmids encoding type 1 and type 2 E2 administered to mice
Number of subjects: 0
Study 17597267 — intervention group
Group type: EXPERIMENTAL
Intervention: IRES-containing plasmids
Number of subjects: 0
Study 15285276 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Imagery (MI) group
Number of subjects: 68
Study 15285276 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 11411907 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncommon TNF A II allele in patients with sarcoidosis-associated erythema nodosum
Number of subjects: 0
Study 11411907 — intervention group
Group type: COMPARATOR
Intervention: Erythema nodosum without underlying sarcoidosis
Number of subjects: 0
Study 9753532 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic Brain Injury (TBI) group
Number of subjects: 36
Study 9753532 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 9753532 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI group
Number of subjects: 36
Study 8119009 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet release for hemostasis
Number of subjects: 100
Study 8119009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tourniquet release)
Number of subjects: 100
Study 1968000 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel and ethinyl oestradiol (0.15 mg levonorgestrel and 0.03 mg ethinyl oestradiol)
Number of subjects: 84
Study 1968000 — intervention group
Group type: COMPARATOR
Intervention: Desogestrel and ethinyl oestradiol (0.15 mg desogestrel and 0.03 mg ethinyl oestradiol)
Number of subjects: 84
Study 880023 — intervention group
Group type: EXPERIMENTAL
Intervention: 14‐4 jejunoileostomy
Number of subjects: 200
Study 880023 — intervention group
Group type: COMPARATOR
Intervention: Modified gastric bypass (90% stomach bypassed)
Number of subjects: 200
Study 31577451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (a PPARÎ³ agonist)
Number of subjects: 3876
Study 31577451 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARÎ³ agonists of the TZD-class
Number of subjects: 3876
Study 28855352 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (50 mg twice a day for 2 weeks)
Number of subjects: 55
Study 28855352 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 55
Study 26683252 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard smoking cessation treatment plus exercise and counseling (n = 35)
Number of subjects: 70
Study 26683252 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation treatment plus a time‐to‐contact control intervention on health education (n = 35)
Number of subjects: 70
Study 24185462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical tenting technique
Number of subjects: 6
Study 24185462 — intervention group
Group type: COMPARATOR
Intervention: Onlay layered technique
Number of subjects: 6
Study 22340231 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.25 mg/kg)
Number of subjects: 40
Study 22340231 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study 19787537 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-avoidance goals
Number of subjects: 138
Study 19787537 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery-avoidance goals
Number of subjects: 138
Study 19787537 — intervention group
Group type: COMPARATOR
Intervention: All four goal conditions
Number of subjects: 138
Study 19787537 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal achievement goals
Number of subjects: 138
Study 18075046 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN‐DBS)
Number of subjects: 20
Study 18075046 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 20
Study 15564946 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 1.0 mg/ml, Fentanyl 1.4 microg/ml, Clonidine 0.5 microg/ml
Number of subjects: 118
Study 15564946 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.9 mg/ml, Fentanyl 3.0 microg/ml, Clonidine 0.3 microg/ml
Number of subjects: 118
Study 15564946 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.6 mg/ml, Fentanyl 2.5 microg/ml, Clonidine 0.8 microg/ml
Number of subjects: 118
Study 15564946 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 1.0 mg/ml, Fentanyl 2.4 microg/ml, Clonidine 1.0 microg/ml
Number of subjects: 118
Study 11949100 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC)
Number of subjects: 30
Study 11949100 — intervention group
Group type: COMPARATOR
Intervention: Conventional cuddling care (CCC)
Number of subjects: 30
Study 8610863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular ketorolac
Number of subjects: 0
Study 8610863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular morphine
Number of subjects: 0
Study 8610863 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intraarticular ketorolac and morphine
Number of subjects: 0
Study 1551352 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg orally)
Number of subjects: 10
Study 1551352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 4067783 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose (Group L)
Number of subjects: 19
Study 4067783 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (Group S)
Number of subjects: 19
Study 4067783 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 30956804 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min/day of in-bed cycling and routine physiotherapy (Cycling)
Number of subjects: 66
Study 30956804 — intervention group
Group type: COMPARATOR
Intervention: Routine physiotherapy alone (Routine)
Number of subjects: 66
Study 29854081 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency electroacupuncture (LEA)
Number of subjects: 5
Study 29854081 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency electroacupuncture (HEA)
Number of subjects: 5
Study 29854081 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture (SEA)
Number of subjects: 5
Study 29854081 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 5
Study 29854081 — intervention group
Group type: COMPARATOR
Intervention: Diabetic group (DM)
Number of subjects: 5
Study 26873052 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental measles vaccine (sMV) administered at median age of 20 months after 1 or 2 doses of primary measles vaccination
Number of subjects: 1756
Study 26873052 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental measles vaccine (sMV) administered at median age of 20 months after 2 doses of primary measles vaccination
Number of subjects: 1756
Study 24853619 — intervention group
Group type: EXPERIMENTAL
Intervention: ExMI
Number of subjects: 158
Study 24853619 — intervention group
Group type: COMPARATOR
Intervention: NSAID
Number of subjects: 158
Study 24853619 — intervention group
Group type: COMPARATOR
Intervention: COC
Number of subjects: 158
Study 22442709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol response to anticipated interaction with dissimilar out-group member
Number of subjects: 0
Study 22442709 — intervention group
Group type: COMPARATOR
Intervention: Cortisol response to anticipated interaction with similar out-group member
Number of subjects: 0
Study 19506136 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory interventions (tracheostomy and noninvasive ventilation)
Number of subjects: 2477
Study 19506136 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheostomy
Number of subjects: 2477
Study 19506136 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Number of subjects: 2477
Study 19506136 — intervention group
Group type: COMPARATOR
Intervention: Death
Number of subjects: 2477
Study 17327305 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride (Wellbutrin XL) during acute phase (10 weeks)
Number of subjects: 93
Study 17327305 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride (Wellbutrin XL) during maintenance phase (24 weeks)
Number of subjects: 93
Study 17327305 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride (Wellbutrin XL)
Number of subjects: 93
Study 15825029 — intervention group
Group type: EXPERIMENTAL
Intervention: gD vaccine with adjuvants (alum and MPL)
Number of subjects: 0
Study 15825029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15825029 — intervention group
Group type: EXPERIMENTAL
Intervention: gD vaccine
Number of subjects: 0
Study 11998240 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' involvement in research
Number of subjects: 0
Study 9523774 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity laser therapy (30 mW .83 microm GaAlAs continuous-wave infrared diode laser)
Number of subjects: 32
Study 9523774 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dummy irradiation)
Number of subjects: 32
Study 7664856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin therapy
Number of subjects: 22
Study 7664856 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22
Study 2696550 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbinac gel applied three times daily
Number of subjects: 231
Study 2696550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 1011296 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (1.8 g administered three times daily with meals)
Number of subjects: 43
Study 1011296 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered three times daily with meals)
Number of subjects: 43
Study 1011296 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 43
Study 1011296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 30777115 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) exercise with very low load (10% of 1-RM) and low volume
Number of subjects: 40
Study 30777115 — intervention group
Group type: COMPARATOR
Intervention: High-intensity resistance exercise (HIRE) (60% of 1-RM)
Number of subjects: 40
Study 30777115 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) exercise with very low load and low volume
Number of subjects: 40
Study 30777115 — intervention group
Group type: COMPARATOR
Intervention: High-intensity resistance exercise (HIRE)
Number of subjects: 40
Study 28240575 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentists' perception of patient interest in sedation/general anesthesia (GA)
Number of subjects: 1076
Study 28240575 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentists' perception of patient interest in sedation/GA depending on cost
Number of subjects: 1076
Study 28240575 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentists' perception of patient fear levels
Number of subjects: 1076
Study 28240575 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentists' perception of patients avoiding dental care
Number of subjects: 1076
Study 28240575 — intervention group
Group type: COMPARATOR
Intervention: Comparison of dentist responses with patient responses from a 2002 national survey
Number of subjects: 1076
Study 25958714 — intervention group
Group type: EXPERIMENTAL
Intervention: VIMA (8% sevoflurane)
Number of subjects: 100
Study 25958714 — intervention group
Group type: COMPARATOR
Intervention: TIVA (propofol to reach 8 mcg/ml)
Number of subjects: 100
Study 23537976 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access catheterization
Number of subjects: 9126
Study 23537976 — intervention group
Group type: COMPARATOR
Intervention: Delayed, provisional eptifibatide
Number of subjects: 9126
Study 21110411 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction/training group (RE)
Number of subjects: 28
Study 21110411 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 28
Study 21110411 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction group (R)
Number of subjects: 28
Study 21110411 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training at maximum lipid-oxidation group (E)
Number of subjects: 28
Study 20232014 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 16
Study 20232014 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 16
Study 20232014 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position
Number of subjects: 16
Study 20232014 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 16
Study 16846663 — intervention group
Group type: EXPERIMENTAL
Intervention: SUCROSE: 9.9% sugar, 132 kcal
Number of subjects: 0
Study 16846663 — intervention group
Group type: COMPARATOR
Intervention: CONTROL: 3% sucrose, 40 kcal
Number of subjects: 0
Study 16846663 — intervention group
Group type: COMPARATOR
Intervention: ASPARTAME: 3% sucrose 40 kcal plus artificial sweeteners ASPARTAME
Number of subjects: 0
Study 15184611 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab 1 mg/kg
Number of subjects: 180
Study 15184611 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab 3 mg/kg
Number of subjects: 180
Study 15184611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 15184611 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab (both doses)
Number of subjects: 180
Study 10906006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin 2.5 mg/day
Number of subjects: 493
Study 10906006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin 5 mg/day
Number of subjects: 493
Study 10906006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin 10 mg/day
Number of subjects: 493
Study 10906006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study 9065720 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplant (BMT) after preparatory regimen of fractionated total body irradiation (FTBI) 1,320 cGy and high-dose etoposide (VP-16) 60 mg/kg
Number of subjects: 33
Study 8443034 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily for 2 weeks
Number of subjects: 10
Study 8443034 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment once daily for 2 weeks
Number of subjects: 10
Study 3537784 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.6 mg twice daily)
Number of subjects: 60
Study 3537784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3537784 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 60